Back to companies

Innate Pharma SA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Innate Pharma SA (Innate Pharma) is a clinical-stage biotechnology company that develops immunotherapies for cancer patients. Its pipeline products include lacutamab, which treats cutaneous T-cell lymphoma and peripheral T-cell lymphoma; monalizumab treats non-small cell lung cancer; and IPH5301, which treats advanced solid tumors. Innate Pharma is also developing IPH6101 for the treatment of acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high myelodysplasia; IPH6401 for the treatment of multiple myeloma. The company utilizes ANKET (Antibody-based NK Cell Engager Therapeutics), a proprietary platform to develop multi-specific NK cell engagers to treat certain types of cancer. It operates in the US and France. Innate Pharma is headquartered in Marseille, Provence - Alpes- Cote d'Azur, France.

 Gain a 360-degree view of Innate Pharma SA and make more informed decisions for your business Gain a 360-degree view of Innate Pharma SA and make more informed decisions for your business Register your interest
Headquarters France
Address 117 Avenue De Luminy, Bp 30191, Marseille, Provence - Alpes- Cote d'Azur, 13009
Website www.innate-pharma.com
Telephone 33 4 30303030
No of Employees 181
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange IPH (EPA)
Revenue (2024) $13.7M -75.7% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ -553.5% (2024 vs 2023)
Market Cap* $170.3M
Net Profit Margin (2024) XYZ -2,586.4% (2024 vs 2023)
* As of and is in US$
View Innate Pharma SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Innate Pharma SA premium industry data and analytics

40+

Catalyst Calendar

Proactively evaluate Innate Pharma SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Clinical Trials

Determine Innate Pharma SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Pipeline Drugs

Identify which of Innate Pharma SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Innate Pharma SA’s relevant decision makers and contact details.

9

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Innate Pharma SA’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products Brands
Pipeline ANKET
Lacutamab: Cutaneous T Cell Lymphoma (Sezary Syndrome / Mycosis Fungoides) and Peripheral T Cell Lymphoma
Monalizumab: Non-small Cell Lung Cancer
XYZ
XYZ
XYZ
Understand Innate Pharma SA portfolio and identify potential areas for collaboration Understand Innate Pharma SA portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Innate Pharma SA Kyowa Kirin Co Ltd Seagen Inc Genfit SA Cellectis SA
Headquarters France Japan United States of America France France
City Marseille Chiyoda-Ku Bothell Loos Paris
State/Province Provence - Alpes- Cote d'Azur Tokyo Washington Bretagne Ile-de-France
No. of Employees 181 5,669 3,256 180 224
Entity Type Public Public Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Irina Staatz-Granzer Chairman Executive Board 2025 64
Pascale Boissel Vice Chairman Executive Board 2025 58
Jonathan Dickinson Chief Executive Officer; Director Executive Board 2024 57
Frederic Lombard Chief Financial Officer; Senior Vice President Senior Management 2021 50
Yannis Morel Chief Operating Officer; Executive Vice President Senior Management 2024 51
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Innate Pharma SA key executives to enhance your sales strategy Gain insight into Innate Pharma SA key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?